Articles published by Immuron Limited
From Immuron Limited
Via GlobeNewswire
Immuron Travelan® continued strong sales growth
October 15, 2024
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 05, 2024
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
From Immuron Limited
Via GlobeNewswire
Immuron Travelan® sales continued strong growth
April 10, 2024
From Immuron Limited
Via GlobeNewswire
Immuron Presentation Australian Biologics Festival 2024
February 21, 2024
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
February 08, 2024
From Immuron Limited
Via GlobeNewswire
Immuron achieves record half yearly Travelan® sales
January 16, 2024
From Immuron Limited
Via GlobeNewswire
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
December 04, 2023
From Immuron Limited
Via GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
November 28, 2023
From Immuron Limited
Via GlobeNewswire
Immuron CEO Steven Lydeamore Investor Webinar Presentation
November 13, 2023
From Immuron Limited
Via GlobeNewswire
Immuron CEO Steven Lydeamore presented at AusBioInvest
October 30, 2023
From Immuron Limited
Via GlobeNewswire
Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023
From Immuron Limited
Via GlobeNewswire
Immuron achieves record quarterly Travelan® sales
October 11, 2023
From Immuron Limited
Via GlobeNewswire
Immuron achieves record monthly Travelan® sales
September 13, 2023
From Immuron Limited
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.